Family Firm Inc. raised its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,212 shares of the medical instruments supplier’s stock after purchasing an additional 6 shares during the period. Family Firm Inc.’s holdings in Becton, Dickinson and were worth $236,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Coho Partners Ltd. raised its stake in shares of Becton, Dickinson and by 24.5% during the 2nd quarter. Coho Partners Ltd. now owns 749,585 shares of the medical instruments supplier’s stock worth $146,252,000 after purchasing an additional 147,472 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of Becton, Dickinson and by 8.0% during the 2nd quarter. Parallel Advisors LLC now owns 1,030 shares of the medical instruments supplier’s stock worth $207,000 after purchasing an additional 76 shares in the last quarter. Sirios Capital Management L P raised its stake in shares of Becton, Dickinson and by 30.9% during the 2nd quarter. Sirios Capital Management L P now owns 635,356 shares of the medical instruments supplier’s stock worth $123,965,000 after purchasing an additional 150,006 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. raised its stake in shares of Becton, Dickinson and by 17.0% during the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 22,829 shares of the medical instruments supplier’s stock worth $4,454,000 after purchasing an additional 3,310 shares in the last quarter. Finally, Sitrin Capital Management LLC raised its stake in shares of Becton, Dickinson and by 2.0% during the 2nd quarter. Sitrin Capital Management LLC now owns 32,929 shares of the medical instruments supplier’s stock worth $6,425,000 after purchasing an additional 640 shares in the last quarter. 87.12% of the stock is owned by institutional investors.

In related news, insider Gary M. Cohen sold 15,512 shares of the company’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the sale, the insider now owns 95,781 shares in the company, valued at $19,517,294.37. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the company’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total value of $1,178,735.11. Following the sale, the insider now owns 12,861 shares in the company, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. Insiders have sold 75,904 shares of company stock worth $15,242,688 in the last quarter. 1.40% of the stock is currently owned by corporate insiders.

Shares of Becton, Dickinson and Company (NYSE BDX) opened at 193.06 on Monday. The firm has a market cap of $43.93 billion, a price-to-earnings ratio of 55.91 and a beta of 1.06. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63. The firm has a 50-day moving average price of $199.01 and a 200-day moving average price of $191.58.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The business had revenue of $3.04 billion for the quarter, compared to analyst estimates of $3.06 billion. During the same quarter in the prior year, the company posted $2.35 earnings per share. Becton, Dickinson and’s revenue was down 5.1% on a year-over-year basis. Equities research analysts anticipate that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be issued a dividend of $0.73 per share. The ex-dividend date is Thursday, September 7th. This represents a $2.92 annualized dividend and a yield of 1.51%. Becton, Dickinson and’s payout ratio is presently 83.43%.

ILLEGAL ACTIVITY WARNING: This article was reported by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.dailypolitical.com/2017/09/25/family-firm-inc-purchases-6-shares-of-becton-dickinson-and-company-bdx.html.

BDX has been the subject of a number of recent research reports. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price target for the company in a research note on Monday, July 17th. Raymond James Financial, Inc. raised Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and cut their price target for the stock from $210.00 to $180.00 in a research note on Friday, June 30th. BidaskClub raised Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. Cowen and Company reaffirmed a “buy” rating and set a $230.00 price target on shares of Becton, Dickinson and in a research note on Monday, August 14th. Finally, Bank of America Corporation reaffirmed a “buy” rating and set a $225.00 price target (up from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Five analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $200.93.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.